Modeling the Economic Impact of a CIZ1B Biomarker Blood Test for Lung Cancer Screening in High-Risk Populations

BackgroundThis study evaluates the economic implications of incorporating a CIZ1B biomarker blood test into lung cancer screening protocols for Medicare-eligible high-risk populations. Despite the proven mortality reduction benefits of low-dose computed tomography (LDCT), its adoption remains low. Barriers such as access disparities, logistical challenges, and the high rate of false positives necessitating invasive follow-up limit LDCTs broader acceptance. The addition of a blood-based biomarker test like CIZ1B could address these barriers by enhancing screening precision, reducing unnecessary diagnostic procedures, and increasing screening participation. MethodsAn economic model was developed to assess the cost savings and public health benefits of integrating CIZ1B in three scenarios: (1) sequential screening with LDCT following a positive biomarker test; (2) using CIZ1B to confirm LDCT-positive cases; and (3) an expanded screening paradigm where CIZ1B reduces barriers, increasing overall screening uptake. The model incorporates Medicare reimbursement rates, prevalence and screening sensitivity data, and cost estimates adjusted for inflation. ResultsResults indicate that integrating CIZ1B testing can yield net savings in the range of $500 Million by avoiding unnecessary biopsies and enabling earlier lung cancer detection and treatment. The expanded screening scenario projects additional savings through higher participation rates. This study highlights the potential of the CIZ1B biomarker to address critical challenges in lung cancer screening, reduce healthcare costs, and improve outcomes for high-risk populations.